Physician profile
Christopher E Watts
NPI 1457598641
$4,085.25
in general payments reported to CMS, 2019-2025
23 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $321 · 2021: $262 · 2022: $526 · 2023: $610 · 2024: $1,071 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,367.08 | 2019-2025 | Clareon, Argos, Centurion |
| Abbvie INC. | $451.79 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Allergan, INC. | $376.00 | 2019-2021 | |
| Bausch Health US, LLC | $307.83 | 2022-2025 | Wellbutrin, Aplenzin |
| Regeneron Healthcare Solutions, INC. | $296.94 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $285.65 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $181.84 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Genentech USA, INC. | $108.89 | 2019-2025 | Vabysmo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.77 | 2022-2024 | Trulance, Uceris |
| Rayner Intraocular Lenses Limited | $97.33 | 2022-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Biogen, INC. | $89.51 | 2022-2024 | Byooviz |
| Sight Sciences, INC. | $83.11 | 2019 | |
| Omeros Corporation | $66.90 | 2019-2021 | |
| Biotissue Holdings INC. | $59.57 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.06 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.74 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $31.54 | 2023 | Syfovre |
| Alimera Sciences, INC. | $24.45 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.99 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.98 | 2021 | |
| Glaukos Corporation | $16.93 | 2025 | Istent Infinite |
| Eyepoint US, INC. | $15.29 | 2019 | |
| Kala Pharmaceuticals, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.